This bill removes a federal rule that requires the White House drug policy office to fight efforts to legalize Schedule I drugs, including marijuana. If passed, the office could review drug laws more neutrally and rely more on research and public health evidence. This could make federal policy more open to state reforms, medical uses, and less punishment-focused responses to drug issues.
